228 related articles for article (PubMed ID: 27095056)
1. A Novel Potent and Highly Specific Inhibitor against Influenza Viral N1-N9 Neuraminidases: Insight into Neuraminidase-Inhibitor Interactions.
Sriwilaijaroen N; Magesh S; Imamura A; Ando H; Ishida H; Sakai M; Ishitsubo E; Hori T; Moriya S; Ishikawa T; Kuwata K; Odagiri T; Tashiro M; Hiramatsu H; Tsukamoto K; Miyagi T; Tokiwa H; Kiso M; Suzuki Y
J Med Chem; 2016 May; 59(10):4563-77. PubMed ID: 27095056
[TBL] [Abstract][Full Text] [Related]
2. Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.
Jia R; Zhang J; Bertagnin C; Cherukupalli S; Ai W; Ding X; Li Z; Zhang J; Ju H; Ma X; Loregian A; Huang B; Zhan P; Liu X
Eur J Med Chem; 2021 Feb; 212():113097. PubMed ID: 33385836
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
Gubareva LV; Penn CR; Webster RG
Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
6. Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus.
Chiu DC; Lin TC; Huang WI; Cheng TJ; Tsai KC; Fang JM
Org Biomol Chem; 2017 Nov; 15(46):9910-9922. PubMed ID: 29159346
[TBL] [Abstract][Full Text] [Related]
7. Tamiphosphor monoesters as effective anti-influenza agents.
Chen CL; Lin TC; Wang SY; Shie JJ; Tsai KC; Cheng YS; Jan JT; Lin CJ; Fang JM; Wong CH
Eur J Med Chem; 2014 Jun; 81():106-18. PubMed ID: 24836064
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of NH
Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y
Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
Wang K; Lei Z; Zhao L; Chen B; Yang F; Liu K; Zhu H; Zhao H; Cao R; Zhang K; Tian Y
Eur J Med Chem; 2020 Jan; 185():111841. PubMed ID: 31708183
[TBL] [Abstract][Full Text] [Related]
10. Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.
Hoffmann A; Schade D; Kirchmair J; Clement B; Sauerbrei A; Schmidtke M
J Virol Methods; 2016 Nov; 237():192-199. PubMed ID: 27659246
[TBL] [Abstract][Full Text] [Related]
11. Divalent oseltamivir analogues as potent influenza neuraminidase inhibitors.
Yan ZL; Liu AY; Wei XX; Zhang Z; Qin L; Yu Q; Yu P; Lu K; Yang Y
Carbohydr Res; 2019 May; 477():32-38. PubMed ID: 30954773
[TBL] [Abstract][Full Text] [Related]
12. Discovery of berberine based derivatives as anti-influenza agent through blocking of neuraminidase.
Enkhtaivan G; Muthuraman P; Kim DH; Mistry B
Bioorg Med Chem; 2017 Oct; 25(20):5185-5193. PubMed ID: 28958846
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.
Kati WM; Montgomery D; Carrick R; Gubareva L; Maring C; McDaniel K; Steffy K; Molla A; Hayden F; Kempf D; Kohlbrenner W
Antimicrob Agents Chemother; 2002 Apr; 46(4):1014-21. PubMed ID: 11897583
[TBL] [Abstract][Full Text] [Related]
15. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.
Song MS; Marathe BM; Kumar G; Wong SS; Rubrum A; Zanin M; Choi YK; Webster RG; Govorkova EA; Webby RJ
J Virol; 2015 Nov; 89(21):10891-900. PubMed ID: 26292325
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase.
Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W
J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388
[TBL] [Abstract][Full Text] [Related]
17. Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors.
Ju H; Zhang J; Sun Z; Huang Z; Qi W; Huang B; Zhan P; Liu X
Eur J Med Chem; 2018 Feb; 146():220-231. PubMed ID: 29407952
[TBL] [Abstract][Full Text] [Related]
18. A sialosyl sulfonate as a potent inhibitor of influenza virus replication.
Hadházi Á; Pascolutti M; Bailly B; Dyason JC; Borbás A; Thomson RJ; von Itzstein M
Org Biomol Chem; 2017 Jun; 15(25):5249-5253. PubMed ID: 28540971
[TBL] [Abstract][Full Text] [Related]
19. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
Ho HT; Hurt AC; Mosse J; Barr I
Antiviral Res; 2007 Dec; 76(3):263-6. PubMed ID: 17868928
[TBL] [Abstract][Full Text] [Related]
20. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors.
Vavricka CJ; Liu Y; Kiyota H; Sriwilaijaroen N; Qi J; Tanaka K; Wu Y; Li Q; Li Y; Yan J; Suzuki Y; Gao GF
Nat Commun; 2013; 4():1491. PubMed ID: 23422659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
